Table 1.
Characteristics of patients with LAPA treated with induction chemotherapy (n = 234)
| Sex ratio (M/F) | 2 (121/103) | |
| Mean age (range) | 67 (29–89) | |
| Performance statusa(%) | ||
| 0–1 | 215 (92) | |
| 2–3 | 19 (8) | |
| Mean BMIa(range) | 24 (14–42) | |
| Weight loss > 5% body weighta(%) | 160 (68) | |
| Diabetes (%) | 15 (36) | |
| Back paina(%) | 152 (65) | |
| Jaundice (%) | 136 (84)b | |
| CA 19–9 serum levela(UI) (range) | 2292 (7–88,300) | |
| Tumour location (%) | ||
| Head | 161 (69) | |
| Body | 57 (24) | |
| Tail | 16 (7) | |
| Tumour classification (%) | ||
| Borderline | 158 (68) | |
| Locally advanced | 76 (32) | |
| Arterial invasiona(%) | 93 (40) | |
| Induction regimen (%) | ||
| FOLFIRINOX | 168 (72) | |
| Gemcitabine | 66 (28) | |
| Mean number of cycles before restaging (range) | 6 (4–8) | |
| Explorative laparotomy (%) | 45 (19) | |
| Treatment after restaging/laparotomy (%) and mean number of cycles (range) after restaging/laparotomy | ||
| FOLFIRINOX | 78 (33) | 4 (0–18) |
| Gemcitabine | 30 (12) | 4 (0–15) |
| Chemoradiation | 126 (54) | 2 (0–19) |
LAPA locally advanced pancreatic adenocarcinoma, BMI body mass index
aat diagnosis
bcalculated for patients with head LAPA